Profile data is unavailable for this security.
About the company
Laboratorios Farmaceuticos ROVI SA (ROVI) is a Spain-based company principally engaged in the pharmaceutical industry. The Company’s main activities include the development and commercialization, nationwide and abroad, of medicines and drugs. Its products are structured into three fields: Diagnostic, which offers contrast mediums for use in magnetic resonance, ultrasound and X-ray diagnostics; Prescription, which distributes medicines under such brands as Hibor, Osseor, Hepadren, Pneumovax-23, Glufan, Corlentor, Exxiv, Calcio y Vitamina D3 Rovi and Absorcol, among others; and Over The Counter (OTC), which comprises the Perspirex, Enerzona, Dentimelo and ColdPack brands. The Company owns such fully consolidated subsidiaries as Gineladius SL, Frosst Iberica SA, Rovi Contract Manufacturing SL and Bertex Pharma GmbH, among others.
- Revenue in EUR (TTM)724.20m
- Net income in EUR121.15m
- Incorporated1946
- Employees2.19k
- LocationLaboratorios Farmaceuticos ROVI SAC/ Julian Camarillo, 35MADRID 28037SpainESP
- Phone+34 913756230
- Fax+34 913047881
- Websitehttps://www.rovi.es/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Xiamen Amoytop Biotech Co Ltd | 407.59m | 114.59m | 3.60bn | 2.42k | 31.34 | 9.79 | -- | 8.84 | 2.31 | 2.31 | 8.22 | 7.40 | 1.03 | 0.8127 | 4.99 | 1,379,284.00 | 29.05 | 22.72 | 33.93 | 26.54 | 92.37 | 91.62 | 28.11 | 23.51 | 3.20 | -- | 0.0448 | 28.80 | 34.13 | 31.02 | 49.00 | 66.70 | 41.17 | 90.06 |
| Anthem BioSciences Ltd | 185.77m | 45.10m | 3.61bn | 2.06k | 80.31 | -- | 63.58 | 19.41 | 8.59 | 8.59 | 35.41 | -- | -- | -- | -- | 9,682,764.00 | -- | -- | -- | -- | 61.25 | -- | 24.27 | -- | -- | -- | -- | -- | 29.96 | -- | 22.86 | -- | -- | -- |
| Simcere Pharmaceutical Group Ltd | 867.68m | 107.46m | 3.61bn | 6.82k | 31.81 | 3.89 | 23.97 | 4.16 | 0.4053 | 0.4053 | 3.26 | 3.31 | 0.5845 | 2.20 | 2.81 | 1,222,488.00 | 7.24 | 8.74 | 9.93 | 12.42 | 81.00 | 78.53 | 12.39 | 15.60 | 1.57 | 4.72 | 0.1453 | 44.12 | 0.4148 | 5.67 | 2.57 | -6.09 | 8.48 | -- |
| Bluestar Adisseo Co | 2.08bn | 145.31m | 3.79bn | 2.93k | 22.71 | 1.60 | -- | 1.82 | 0.4447 | 0.4447 | 6.37 | 6.31 | 0.7204 | 5.30 | 8.18 | 5,834,541.00 | 5.03 | 5.20 | 6.05 | 6.63 | 27.69 | 29.69 | 6.99 | 8.12 | 1.12 | 10.31 | 0.1377 | 30.01 | 17.83 | 6.88 | 2,208.66 | 3.95 | 5.53 | -7.02 |
| Shanghai Junshi Biosciences Co Ltd | 302.82m | -115.84m | 3.80bn | 2.67k | -- | 5.66 | -- | 12.56 | -0.96 | -0.96 | 2.51 | 6.05 | 0.2203 | 0.8436 | 5.48 | 963,148.80 | -9.45 | -17.61 | -12.31 | -22.00 | 81.59 | 68.46 | -42.92 | -84.56 | 1.43 | -23.04 | 0.3629 | -- | 29.67 | 20.24 | 43.90 | -- | -4.33 | -- |
| TG Therapeutics Inc | 448.16m | 377.03m | 3.81bn | 374.00 | 10.26 | 7.28 | 10.11 | 8.51 | 2.78 | 2.78 | 3.29 | 3.91 | 0.6603 | 0.6733 | 2.79 | 1,573,663.00 | 55.55 | -42.93 | 67.33 | -52.55 | 85.34 | -- | 84.13 | -142.45 | 2.89 | 3.77 | 0.2878 | -- | 40.80 | 364.59 | 84.52 | -- | -19.24 | -- |
| Humanwell Healthcare Group Co Ltd | 2.95bn | 174.23m | 3.82bn | 17.65k | 21.97 | 1.66 | -- | 1.30 | 0.8741 | 0.8741 | 14.84 | 11.59 | 0.6519 | 3.63 | 2.48 | 1,369,715.00 | 5.00 | 6.40 | 8.73 | 12.55 | 44.53 | 43.83 | 7.67 | 9.90 | 1.40 | 362.14 | 0.2889 | 25.97 | 3.71 | 3.13 | -37.70 | 11.15 | 4.75 | 56.54 |
| Amneal Pharmaceuticals Inc | 2.47bn | 4.97m | 3.93bn | 8.10k | 897.09 | -- | 15.63 | 1.59 | 0.0165 | 0.0165 | 9.17 | -0.3483 | 0.8313 | 3.07 | 3.59 | 362,340.60 | 1.63 | -2.12 | 2.32 | -2.68 | 36.76 | 35.94 | 1.96 | -3.47 | 1.42 | 1.47 | 1.02 | -- | 16.73 | 11.43 | -39.16 | -- | -5.10 | -- |
| Beijing Tiantan Biological Products Corp | 783.41m | 160.51m | 3.93bn | 5.30k | 24.49 | 2.81 | -- | 5.02 | 0.6656 | 0.6656 | 3.25 | 5.80 | 0.4002 | 0.9382 | 11.21 | 1,212,453.00 | 11.25 | 11.93 | 16.06 | 16.79 | 45.65 | 50.69 | 28.10 | 29.69 | 3.08 | -- | 0.0152 | 16.24 | 16.44 | 12.94 | 39.58 | 20.45 | 15.19 | 23.56 |
| Laboratorios Farmaceuticos ROVI SA | 724.20m | 121.15m | 3.95bn | 2.19k | 32.88 | 6.32 | 26.17 | 5.45 | 2.34 | 2.34 | 14.14 | 12.18 | 0.8047 | 0.7912 | 3.84 | 332,354.30 | 13.46 | 19.71 | 17.65 | 26.62 | 63.87 | 60.82 | 16.72 | 20.72 | 1.32 | 75.24 | 0.1634 | 35.00 | -7.93 | 14.90 | -19.64 | 28.37 | 8.95 | 39.80 |
| China Medical System Holdings Ltd | 959.65m | 201.52m | 3.98bn | 6.10k | 19.57 | 1.91 | 17.08 | 4.15 | 0.7732 | 0.7732 | 3.68 | 7.90 | 0.4239 | 3.14 | 6.12 | 1,449,608.00 | 8.85 | 16.35 | 9.88 | 18.70 | 71.47 | 75.03 | 20.88 | 32.20 | 5.28 | -- | 0.0417 | 40.16 | -6.79 | 4.22 | -32.54 | -3.75 | 6.01 | -2.60 |
| Hikma Pharmaceuticals Plc | 2.73bn | 312.63m | 4.02bn | 9.31k | 12.89 | 1.88 | 8.26 | 1.47 | 1.22 | 1.22 | 10.67 | 8.38 | 0.6238 | 1.81 | 3.23 | 255,362.20 | 7.17 | 7.19 | 10.75 | 10.00 | 43.65 | 49.35 | 11.50 | 11.87 | 0.7174 | 7.62 | 0.3792 | 44.05 | 9.77 | 7.45 | 88.95 | -5.88 | 4.79 | 10.29 |
| GlaxoSmithKline Pharmaceuticals Ltd | 353.64m | 95.00m | 4.09bn | 3.11k | 43.05 | -- | 40.36 | 11.56 | 60.26 | 60.26 | 224.34 | -- | -- | -- | -- | 12,209,250.00 | -- | 15.30 | -- | 25.66 | 64.24 | 56.70 | 26.86 | 16.77 | -- | 452.52 | -- | 144.35 | 8.56 | 3.06 | 57.23 | 53.14 | -31.03 | 16.00 |
Data as of Feb 16 2026. Currency figures normalised to Laboratorios Farmaceuticos ROVI SA's reporting currency: Euro EUR
9.06%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 04 Feb 2026 | 675.11k | 1.32% |
| T. Rowe Price Hong Kong Ltd.as of 31 Dec 2025 | 654.66k | 1.28% |
| Santander Private Banking Gestion SA SGIICas of 31 Dec 2025 | 586.85k | 1.15% |
| BN & Partners Capital AGas of 28 Nov 2025 | 517.39k | 1.01% |
| Invesco Asset Management Ltd.as of 04 Nov 2025 | 501.09k | 0.98% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 446.39k | 0.87% |
| Shareholder Value Management AGas of 30 Jan 2026 | 385.11k | 0.75% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 312.27k | 0.61% |
| Bestinver Gesti�n SA SGIICas of 31 Dec 2025 | 284.27k | 0.56% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 279.39k | 0.55% |
More ▼
Data from 30 Sep 2025 - 30 Jan 2026Source: FactSet Research Systems Inc.
